This move is archived. Current quotes and coverage live on the stock page.
Follow PRN
Profound Medical Corp faced a challenging session, with its stock dropping significantly.
Shares of Profound Medical Corp (PRN.TO) fell yesterday, closing down 4.68% at CA$11.21. This decline highlights ongoing concerns surrounding the company's recent performance and market sentiment.
Advertisement
Profound Medical Corp
PRN.TO
PRN.TO
Profound Medical Corp
WealthAwesomeMarket cap
$359.19M
52W high
$12.40
52W low
$6.52
1W change
+17.58%
Beta
0.56
Analyst Price Targets
Based on analyst covering PRN · as of Sep 17, 2026
Wall Street analysts forecast PRN stock price to rise 154.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$25.03
+154.6% Upside
Current Price
C$9.83
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on PRN's historical volatility
30-Day Vol
76.4%
Annualized
90-Day Vol
61.7%
Annualized
Trend (90d)
-0.4%
Annualized drift
90d Mean
C$9.82
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$9.83 | C$7.55 – C$12.79 |
| 60 trading days | C$9.82 | C$6.76 – C$14.26 |
| 90 trading days | C$9.82 | C$6.22 – C$15.50 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should closely monitor Profound Medical's upcoming financial results and trial outcomes as they could significantly impact stock performance.
4.68% Decline in Stock Value
Profound Medical's market cap now stands at CA$427.33 million, reflecting investor caution amidst recent trial results.
Bull case
If the upcoming trials show positive results, or if the company can effectively demonstrate the efficacy of its TULSA-PRO® system, we might see a rebound in stock value.
Bear case
On the other hand, if clinical trials continue to face setbacks, like the recent CAPTAIN trial, investor confidence may wane further, leading to additional declines.
Market Reaction to Recent Trials
Advertisement
Profound Medical's stock decline can be attributed to disappointing results from the CAPTAIN trial, which did not meet its primary endpoint. This news has raised concerns among investors regarding the company's future prospects and its ability to deliver on its promises in the competitive healthcare market.
Upcoming Financial Results
Investors are now looking ahead to the scheduled release of Profound Medical's Q2 2026 financial results on August 6, 2026. This report will be crucial for assessing the company's financial health and could significantly influence stock performance. For more details, visit our Profound Medical stock page.
Investor Sentiment and Future Outlook
The recent drop in stock price reflects a broader sentiment of caution among investors. As Profound Medical navigates through its clinical trials and prepares for upcoming results, the market will be watching closely for signs of recovery or further decline. For ongoing updates, check our Profound Medical stock page.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
